| Objective:To explore the correlation of serum IL-6、IL-18、CC16 levels with lung function and the CAT scores in stable chronic obstructive pulmonary disease(COPD)patients.Methods:1.Objective:200 cases(male 119 cases,female 81 cases,mean age 67.93±8.19 years)with COPD at stable stage were included in the COPD group.100 cases(male 49 cases,female 51 cases,mean age 63.35±7.87 years)with healthy physical status during the same period were collected in control group.There was no significant difference in age,gender and smoking index between the two groups(P>0.05).2.Research methods:All enrolled subjects needed to complete the history collection and questionnaire survey and finish the following items:(1)Collected the blood samples in the morning and detected the serum IL-6,IL-18,CC16 levels by ELISA for the two groups.(2)The COPD group and normal group were divided into four subgroups according to the smoking history,and compared the serum IL-6,IL-18,CC16 levels of the four subgroups.(3)Completed the CAT score questionnaire for all COPD patients and analyzedthe correlation of CAT score withthe serum IL-6,IL-18,CC16 levels.(4)Tested the lung function for all subjects,and classified the COPD patients into Ⅰ-Ⅳ class according to the 2007 GOLD classification.The Ⅰ-Ⅱ class was the mild-moderate subgroup and theⅢ-Ⅳ class was thesevere-very severe subgroup.Assessed the differences of the serum IL-6,IL-18,CC16 levelsinstable COPD patients with various severity,and analyzedthe correlation of the lung function FEV1%,FEV1/FVC with the serumIL-6,IL-18,CC16 levels and CAT scores.Results:1.Compared with the control group,the serum IL-6,IL-18 levels increased significantly and the CC16 serum level decreased in the COPD group(P<0.001).2.Compared with the normal subgroup without smoking history,theserum IL-6 level increased significantly in the other three subgroups(P<0.05).The serum IL-6 level of COPD subgroup with smoking history was higher than the normal subgroup with smoking history(P<0.05).Compared with the normal subgroup without smoking history,the IL-18 level significantly increased in other three subgroups,but the CC16 level decreased obviously(P<0.05).Compared with the normal subgroup with smoking history,the level of IL-18 increased and the level of CC16 decreased in the COPD subgroup with or without smoking history(P<0.05).3.Compared with mild-moderatesubgroup,the serum IL-6,IL-18 levels increased and the CC16 levels decreased significantly in the severe-very severesubgroup inCOPD patients(P<0.01).4.The correlation analysis:the FEV1%of COPD patients was negatively correlated with the serum IL-6,IL-18 levels(r=-0.765,r=-0.721,p<0.01)and positively correlated with the serum CC16 level(r=0.397,p<0.01).The FEV1/FVC of COPD patients was negatively correlated with the serum IL-6,IL-18 levels(r=-0.466,r=-0.408,p<0.01)and positively correlated with the serum CC16 level(r=0.309,p<0.01).The CAT score was positively correlated with the serum concentration of IL-6,IL-18(r=0.500,r=0.533,p<0.01),but not correlated with the level of serum CC16(r=-0.167,p=0.18).The CAT score was negatively related to the FEV1%and FEV1/FVC in stable COPD(r=-0.634,r=-0.496,p<0.01).Conclusions:1.The IL-6,IL-18 and CC16 involved in the the developmentprocess of inflammation and lung tissue damage in stableCOPD,and theycould be the effective indexes for assessing the disease progression of COPD patients.2.Smoking was an important factor aggravating the systemic inflammatory reaction and airway injury in COPD patients,and the IL-6,IL-18,CC16 played an important role in this process.3.The variation of the serum IL-6,IL-18 levels might related to the life quality of COPD patients at stable stage. |
PDF Full Text Request